Generex Biotechnology Corporation
GNBT · OTC
4/30/2021 | 1/31/2021 | 10/31/2020 | 7/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | -0.05 | 0.20 | -0.00 |
| FCF Yield | 8.99% | -15.89% | -24.62% | -14.71% |
| EV / EBITDA | 1.33 | -0.70 | -1.60 | -1.60 |
| Quality | ||||
| ROIC | -58.43% | -9,750.63% | -6,971.60% | -20.72% |
| Gross Margin | -218.89% | 0.00% | 73.62% | 71.85% |
| Cash Conversion Ratio | 0.07 | 0.04 | 0.12 | 0.05 |
| Growth | ||||
| Revenue 3-Year CAGR | -55.12% | -43.72% | -5.72% | 55.84% |
| Free Cash Flow Growth | 158.84% | 26.61% | -110.58% | 28.65% |
| Safety | ||||
| Net Debt / EBITDA | 0.72 | -0.44 | -1.03 | -1.16 |
| Interest Coverage | -6.05 | -14.60 | -13.85 | -3.19 |
| Efficiency | ||||
| Inventory Turnover | 0.28 | 0.17 | 0.03 | 0.22 |
| Cash Conversion Cycle | -55,316.68 | -33,176.12 | -126,119.81 | -12,665.04 |